Israel Englander Protagonist Therapeutics, Inc Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$24.66 - $34.8 $22.6 Million - $31.9 Million	915,418 Added 2135.58%	958,283 $33.2 Million
Q1 2024 May 15, 2024	SELL	$21.79 - $32.15 $2.32 Million - $3.42 Million	-106,298 Reduced 71.26%	42,865 $1.24 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $2.85 Million - $4.75 Million	-202,647 Reduced 57.6%	149,163 $3.42 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $13.9 Million - $22.6 Million	-770,532 Reduced 68.65%	351,810 $9.72 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $2.4 Million - $5.66 Million	-223,047 Reduced 16.58%	1,122,342 $25.8 Million
Q4 2022 Feb 14, 2023	BUY	$7.36 - $11.17 $8.44 Million - $12.8 Million	1,147,367 Added 579.41%	1,345,389 $14.7 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $7.01 Million - $10.4 Million	-891,506 Reduced 81.82%	198,022 $1.67 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $4.44 Million - $16.1 Million	629,413 Added 136.79%	1,089,528 $8.62 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $1.61 Million - $2.49 Million	69,042 Added 17.65%	460,115 $10.9 Million
Q4 2021 Feb 14, 2022	SELL	$17.63 - $37.1 $2.32 Million - $4.89 Million	-131,798 Reduced 25.21%	391,073 $13.4 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $6.57 Million - $25.2 Million	507,431 Added 3286.47%	522,871 $9.27 Million
Q2 2021 Aug 16, 2021	BUY	$25.57 - $44.88 $116,292 - $204,114	4,548 Added 41.76%	15,440 $693,000
Q1 2021 May 17, 2021	SELL	$19.02 - $31.15 $225,843 - $369,875	-11,874 Reduced 52.16%	10,892 $282,000
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $420,943 - $572,109	22,766 New	22,766 $459,000
Q3 2020 Nov 16, 2020	SELL	$15.19 - $22.4 $5.84 Million - $8.61 Million	-384,205 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $260,165 - $791,845	42,030 Added 12.28%	384,205 $6.79 Million
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $2.73 Million - $4.65 Million	-504,819 Reduced 59.6%	342,175 $2.42 Million
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $42,688 - $122,421	9,102 Added 1.09%	846,994 $5.97 Million
Q3 2019 Nov 14, 2019	BUY	$9.41 - $16.56 $252,432 - $444,238	26,826 Added 3.31%	837,892 $10.1 Million
Q2 2019 Aug 15, 2019	BUY	$8.98 - $12.96 $2.82 Million - $4.07 Million	314,066 Added 63.19%	811,066 $9.82 Million
Q2 2019 Aug 14, 2019	SELL	$8.98 - $12.96 $3.56 Million - $5.13 Million	-396,155 Reduced 44.35%	497,000 $3.57 Million
Q1 2019 May 14, 2019	BUY	$6.5 - $13.77 $1.32 Million - $2.8 Million	203,004 Added 29.41%	893,155 $11.2 Million
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $2.16 Million - $3.59 Million	-343,647 Reduced 33.24%	690,151 $4.65 Million
Q3 2018 Nov 14, 2018	BUY	$6.82 - $11.26 $5.49 Million - $9.07 Million	805,517 Added 352.86%	1,033,798 $10.6 Million
Q2 2018 Aug 14, 2018	SELL	$5.99 - $9.1 $553,823 - $841,367	-92,458 Reduced 28.83%	228,281 $1.53 Million
Q1 2018 May 15, 2018	BUY	$8.46 - $23.08 $1.08 Million - $2.95 Million	128,009 Added 66.42%	320,739 $2.76 Million
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $801,319 - $1.15 Million	55,378 Added 40.32%	192,730 $4.01 Million
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $1.46 Million - $2.47 Million	137,352	137,352 $2.43 Million

Others Institutions Holding PTGX

# of Institutions

248

Shares Held

56.7M

Call Options Held

76.3K

Put Options Held

114K

Farallon Capital Management LLC San Francisco, CA

5.86M
Shares

$230 Million
1.32% of portfolio
Black Rock Inc. New York, NY

5.76M
Shares

$226 Million
0.0% of portfolio
Rtw Investments, LP New York, NY

5.43M
Shares

$213 Million
3.89% of portfolio
Vanguard Group Inc Valley Forge, PA

4.22M
Shares

$166 Million
0.0% of portfolio
State Street Corp Boston, MA

3.18M
Shares

$125 Million
0.01% of portfolio

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $1.93B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account